|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Femcon_Fe
|
|
gptkbp:category
|
gptkb:X
|
|
gptkbp:class
|
combination oral contraceptive
|
|
gptkbp:clinical_trial
|
conducted for safety and efficacy
|
|
gptkbp:complications
|
may occur
|
|
gptkbp:contraindication
|
liver disease
certain cancers
history of blood clots
smoking over age 35
|
|
gptkbp:distributes
|
gptkb:stock_market_index
|
|
gptkbp:dosage_form
|
take as soon as remembered
chewable tablet
if missed for 2 days, use backup contraception
|
|
gptkbp:effective_date
|
2000-09-01
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:has_ability
|
0.4 mg norethindrone
35 mcg ethinyl estradiol
|
|
gptkbp:healthcare
|
recommended before use
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Femcon Fe
|
|
gptkbp:indication
|
pregnancy prevention
|
|
gptkbp:ingredients
|
gptkb:norethindrone
gptkb:ethinyl_estradiol
|
|
gptkbp:interacts_with
|
gptkb:St._John's_Wort
antibiotics
anticonvulsants
HIV medications
|
|
gptkbp:is_effective_against
|
over 99% with perfect use
91% with typical use
|
|
gptkbp:is_monitored_by
|
blood pressure recommended
|
|
gptkbp:label
|
gptkb:Teva_Pharmaceuticals_USA,_Inc.
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Teva_Pharmaceuticals
|
|
gptkbp:market
|
marketed
|
|
gptkbp:packaging
|
available online
blister pack
|
|
gptkbp:population
|
provided with prescription
|
|
gptkbp:requires
|
prescription only
|
|
gptkbp:side_effect
|
headache
nausea
weight gain
breast tenderness
mood changes
reported in clinical studies
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:type_of_care
|
important for effectiveness
|
|
gptkbp:bfsParent
|
gptkb:ethinylestradiol
|
|
gptkbp:bfsLayer
|
6
|